'Vampire' Bacteria Has Potential as Living Antibiotic

A vampire-like bacteria that leeches onto specific other bacteria - including certain human pathogens - has the potential to serve as a living antibiotic for a range of infectious diseases, a new study indicates.

The bacterium, Micavibrio aeruginosavorus, was discovered to inhabit wastewater nearly 30 years ago, but has not been extensively studied because it is difficult to culture and investigate using traditional microbiology techniques. However, biologists in the University of Virginia's College of Arts & Sciences, Martin Wu and graduate student Zhang Wang, have decoded its genome and are learning "how it makes its living," Wu said.

The bacterium "makes its living" by seeking out prey - certain other bacteria - and then attaching itself to its victim's cell wall and essentially sucking out nutrients. Unlike most other bacteria, which draw nutrients from their surroundings, M. aeruginosavorus can survive and propagate only by drawing its nutrition from specific prey bacteria. This kills the prey - making it a potentially powerful agent for destroying pathogens.

One bacterium it targets is Pseudomonas aeruginosavorus, which is a chief cause of serious lung infections in cystic fibrosis patients.

"Pathologists may eventually be able to use this bacterium to fight fire with fire, so to speak, as a bacterium that will aggressively hunt for and attack certain other bacteria that are extremely harmful to humans," Wu said.

His study, detailing the DNA sequence of M. aeruginosavorus, is published online in the journal BMC Genomics (The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1471-2164/12/453). It provides new insights to the predatory lifestyle of the bacterium and a better understanding of the evolution of bacterial predation in general.

"We used cutting-edge genomic technology in our lab to decode this bacterium's genome," Wu said. "We are particularly interested in the molecular mechanisms that allow it to hunt for and attack prey. This kind of investigation would have been extremely difficult and expensive to do only a few years ago."

He noted that overuse of traditional antibiotics, which work by either inhibiting bacteria propagation or interfering with cell wall formation, are creating so-called "super bugs" that have developed resistances to treatment strategies. He suggests that new approaches are needed for attacking pathogens without building up their resistance.

Additionally, because M. aeruginosavorus is so selective a feeder, it is harmless to the thousands of beneficial bacteria that dwell in the general environment and in the human body.

"It is possible that a living antibiotic such as M. aeruginosavorus - because it so specifically targets certain pathogens - could potentially reduce our dependence on traditional antibiotics and help mitigate the drug-resistance problem we are now facing," Wu said.

Another benefit of the bacterium is its ability to swim through viscous fluids, such as mucus. P. aeruginosavorus, the bacterium that colonizes the lungs of cystic fibrosis patients, creates a glue-like biofilm, enhancing its resistance to traditional antibiotics. Wu noted that the living cells of M. aeruginosavorus can swim through mucus and biofilm and attack P. aeruginosavorus.

M. aeruginosavorus also might have industrial uses, such as reducing bacteria that form biofilms in piping, and for medical devices, such as implants that are susceptible to the formation of biofilms.

Wu said M. aeruginosavorus requires further study for a more thorough understanding of its gene functions. He said genetic engineering would be required to tailor the predatory attributes of the bacterium to specific uses in the treatment of disease.

"We have a map now to work with, and we will see where it leads," he said.

Wu and Wang's co-author is Daniel E. Kadouri, a researcher at the New Jersey Dental School. Kadouri is interested in M. aeruginosavorus as an agent for fighting oral biofilms, such as plaque.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Roche's personalised medicine entrectinib shrank t…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive data from the Phase I/II STARTRK-NG study, evaluating the investigational medicine entrectinib in children and adole...